Engineered Veterinary Vectored Immunotherapy and Vaccines: EVVIVAX

Evvivax scientists will be at VCS and present the following abstract:

Tel-eVax™: a Genetic Vaccine targeting Telomerase for treatment of Canine Malignant Lymphoma

Evvivax data shiw that Tel-eVax™ in combination with chemotherapy is safe and immunogenic in canine patients. These data confirm the therapeutic efficacy of dTERT vaccine and hold promise for the treatment of dogs affected by other cancer types. Most importantly, the study outlines the relevance of canine patients as relevant preclinical models for human cancer vaccines.


About Tel-eVax:

Tel-eVax targets Telomerase, the enzyme that maintains telomeres and prevents them from shortening during cell division. Telomerase is upregulated in many tumor cells, which enables the continued and uncontrolled proliferation of the malignant cells that drive tumor growth and progression.

Tel-eVax has shown efficacy for canine B-cell Lymphoma in three trials and is currently being evaluated in other tumor types

For more information:

Evvivax: Our Vaccines

Veterinary Cancer Society - Join us in Portland, Oregon

22 September 2017 - EVVIVAX scientists successfully treat an Asian Elephant with Electrochemotherapy

EVVIVAX has moved from mice, to cats and dogs and now Elephants!

EVVIVAX is proud to be part of the team treating Juno, a beautiful 50 year old Asian Elephant diagnosed with inoperable breast cancer.

10-12 Apr 2017 - EVVIVAX at the World Veterinary Vaccine Conference, Washington DC, USA

Join us at the Annual World Veterinary Vaccine Congress in Washington DC!

7 Apr 2017: EVVIVAX Visiting PennVet, Philadelphia, USA

Dr Luigi Aurisicchio, CEO at EVVIVAX and President at VITARES, is very happy to visit the School of Veterinary Medicine at the

Evvivax News